Veru Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
/ 
Frequently asked questions
To buy Veru Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Veru Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Veru Inc. is VERU:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Veru Inc. has its primary listing on NASDAQ (Small cap). You can trade Veru Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Veru Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Veru Inc. as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Veru Inc..